Cargando…
Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling
The investigational ticagrelor‐neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the antiplatelet effects of ticagrelor. However, the dynamic interaction of ticagrelor, the ticagrelor active metabolite (TAM), and MEDI2452, makes pharmacokinetic (PK) analysis...
Autores principales: | Almquist, J, Penney, M, Pehrsson, S, Sandinge, A‐S, Janefeldt, A, Maqbool, S, Madalli, S, Goodman, J, Nylander, S, Gennemark, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131888/ https://www.ncbi.nlm.nih.gov/pubmed/27310493 http://dx.doi.org/10.1002/psp4.12089 |
Ejemplares similares
-
Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452
por: Sandinge, Ann-Sofie, et al.
Publicado: (2018) -
Population pharmacokinetic–pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers
por: Kathman, Steven J., et al.
Publicado: (2021) -
New alternative to antidotes for novel oral anticoagulants and ticagrelor in the case of severe bleeding
por: Honore, Patrick M., et al.
Publicado: (2020) -
Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
por: Chong, Jia, et al.
Publicado: (2020) -
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015)